Expertise in
18
conditions

Dr. Alok A. Khorana

Oncology
10201 Carnegie Avenue, 
Cleveland, OH 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
18
conditions
10201 Carnegie Avenue, 
Cleveland, OH 

Overview

Alok Khorana is an Oncologist practicing medicine in Cleveland, Ohio.

Dr. Khorana is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Venous Thromboembolism (VTE), Pancreatic Cancer, Colorectal Cancer, Pancreatectomy, and Endoscopy.

Dr. Khorana is board certified in American Board Of Internal Medicine, 2002. He is actively involved in clinical research, co-authoring 274 peer reviewed articles and participating in 6 clinical trials. Dr. Khorana is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in NY

Board Certifications

American Board Of Internal Medicine, 2002

Fellowships

University of Rochester Medical Center

Hospital Affiliations

Hillcrest Hospital
Cleveland Clinic Avon Hospital
Cleveland Clinic
Akron General Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AultCare
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
CommuniCare Advantage
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Primetime Health Plan
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE PART D
Provider Partners Health Plan
  • MEDICARE SNP
SummaCare
  • HMO
  • PPO
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Univera Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

Cleveland Clinic Main Campus
10201 Carnegie Avenue, Cleveland, OH 44106
Other Locations
Cleveland Clinic Main Campus
9500 Euclid Avenue, Cleveland, OH 44195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder
A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Drug, Other
Study Drugs: Tucatinib, Trastuzumab, Ramucirumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: January 03, 2023
Intervention Type: Drug
Study Drugs: CPI 613, mFolfirinox, Folfirinox
Study Phase: Phase 3
A Randomized, Phase II Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients
A Randomized, Phase II Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients
Enrollment Status: Completed
Publish Date: July 08, 2021
Intervention Type: Drug
Study Drug: Enoxaparin
Study Phase: Phase 2
A Prospective, Multinational, Multi-Center, Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy, Safety and Tolerability of siG12D-LODER in Combination With Standard of Care Chemotherapy in the Treatment of Patients With Locally Advanced Pancreatic Cancer
A Prospective, Multinational, Multi-Center, Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy, Safety and Tolerability of siG12D-LODER in Combination With Standard of Care Chemotherapy in the Treatment of Patients With Locally Advanced Pancreatic Cancer
Enrollment Status: Unknown
Publish Date: July 02, 2021
Intervention Type: Drug
Study Drugs: siG12D-LODER, Gemcitabine+Nab-Paclitaxel, Folfirinox
Study Phase: Phase 2
View 5 Less Clinical Trials

274 Total Publications

Guidelines Can Be Lifesaving: The Vermont Model of Thromboprophylaxis Implementation.
Guidelines Can Be Lifesaving: The Vermont Model of Thromboprophylaxis Implementation.
Journal: JCO oncology practice
Published: May 01, 2026
Similar Doctors
Expertise in
27
conditions
Dr. David M. Peereboom
Oncology | Hematology Oncology
Expertise in
27
conditions
Dr. David M. Peereboom
Oncology | Hematology Oncology
Referral may be required
Before you request

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
 (0.1 miles away)
866-223-8100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Peereboom is an Oncologist and a Hematologist Oncology provider practicing medicine in Cleveland, Ohio. Dr. Peereboom is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioblastoma, Glioma, Astrocytoma, and Bone Marrow Aspiration. Dr. Peereboom is board certified in United Council For Neurological Subspecialties, 2008. Dr. Peereboom is currently accepting new patients.

Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

University Hospitals

11100 Euclid Ave, 
Cleveland, OH 
 (0.6 miles away)
216-844-1228
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Afshin Dowlati is an Oncologist practicing medicine in Cleveland, Ohio. Dr. Dowlati is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, and Bone Marrow Aspiration. Dr. Dowlati is currently accepting new patients.

Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required
Before you request

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
 (0.1 miles away)
866-223-8100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Moshe Ornstein is an Oncologist practicing medicine in Cleveland, Ohio. Dr. Ornstein is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Gamma Knife Radiosurgery. Dr. Ornstein is board certified in American Board Of Internal Medicine, 2017. Dr. Ornstein is currently accepting new patients.

Frequently Asked Questions about Dr. Alok A. Khorana

How do I make an appointment with Dr. Alok A. Khorana?

You can book an appointment with Dr. Alok A. Khorana by calling their office at 866-223-8100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Alok A. Khorana a top-rated expert for Venous Thromboembolism (VTE)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Alok A. Khorana is classified as an Elite expert for Venous Thromboembolism (VTE), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Alok A. Khorana specialize in?

While Dr. Alok A. Khorana is a Oncology, they have specific expertise in Venous Thromboembolism (VTE), Pancreatic Cancer, and Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Alok A. Khorana participate in research or clinical trials?

Yes. Dr. Alok A. Khorana has published 274 articles and abstracts on conditions like Venous Thromboembolism (VTE). You can view a list of Dr. Alok A. Khorana's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Alok A. Khorana accept my insurance?

Dr. Alok A. Khorana accepts most major insurance plans, including Aetna and Ambetter. We recommend calling the office directly at 866-223-8100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Khorana's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 31 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile